Investor Awareness

HomeAbout Investor AwarenessClient ServicesClient Success StoriesManagement TeamClient ProfilesContact Us

Client Profiles

 

Jaguar Animal HealthJaguar Animal Health, Inc.
Nasdaq: JAGX
www.jaguaranimalhealth.com
Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses. Canalevia™ is Jaguar’s lead prescription drug product candidate, intended for the treatment of various forms of diarrhea in dogs. Equilevia™ (formerly referred to as SB-300) is Jaguar’s prescription drug product candidate for the treatment of gastrointestinal ulcers in horses. Canalevia™ and Equilevia™ contain ingredients isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™ Foal are the Company’s lead non-prescription products. Neonorm™ is a standardized botanical extract derived from the Croton lechleri tree. Canalevia™ and Neonorm™ are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has nine active investigational new animal drug applications, or INADs, filed with the FDA and intends to develop species-specific formulations of Neonorm™ in six additional target species, formulations of Equilevia™ in horses, and Canalevia™ for cats and dogs.

Yahoo Data and NewsCompany Web Site

ICON LEGEND
Yahoo Data and News
 Yahoo Finance Data & News
Company Profile Company Profile (PDF)
Company Web Site Company Web Site

News and Updates

Jaguar Animal Health & Napo Pharma. Announce Filing of Two Orphan Drug Designation Applications
SAN FRANCISCO - - Jun. 5, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, and Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, today announced Napo’s filing of orphan drug designation applications with the U.S. Food & Drug Administration (FDA) for Mytesi® for two areas of serious unmet medical needs: Congenital diarrheal disorders and diarrhea associated with short bowel syndrome. (full story)

Jaguar Animal Health Appoints Dr. Pravin Chaturvedi to Chair Scientific Adv.
SAN FRANCISCO-- May 10, 2017 - - Jaguar Animal Health, Inc. (JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, and Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, today announced the appointment of Dr. Pravin Chaturvedi, a highly experienced drug development veteran who has spent more than 25 years in the pharmaceutical/biotech industry, as Chair of the combined company’s Scientific Advisory Board, following the expected close of the proposed merger of Jaguar and Napo. Dr. Chaturvedi has served as Chair of Napo’s Scientific Advisory Board since March 27, 2017. Dr. Chaturvedi is responsible for providing direction on strategy, tactics and oversight regarding advancing the development and commercialization of the companies’ drug pipelines, including, but not limited to, Mytesi® and SB-300. (full story)

Remark Holdings Reports First Quarter 2017 Results
LAS VEGAS, May 15, 2017 -- Remark Holdings, Inc. (MARK), a global digital media technology company, reported its financial results for the first quarter of 2017.

(full story)

More Articles
 

Upcoming Events

There are no events to display at this time.
Complete Events List
 

Remark HoldingsRemark Holdings, Inc.
NASDAQ: MARK
www.remarkmedia.com
Remark Holdings, Inc. (MARK) owns, operates and acquires innovative digital media properties across multiple verticals that deliver culturally relevant, dynamic content that attracts and engages users on a global scale.  The company leverages its unique digital media assets to target the Millennial demographic, which provides it with access to fast-growing, lucrative markets.  The company is headquartered in Las Vegas, Nevada, with additional operations in Los Angeles, California and in Beijing, Shanghai, Hangzhou and Chengdu, China. For more information, please visit the company's website at www.remarkmedia.com.
Yahoo Data and NewsCompany Web Site

Ritter PharmaceuticalsRitter Pharmaceuticals, Inc.
NASDAQ: RTTR
ritterpharmaceuticals.com
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. We are advancing human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of gut modulation into applications intended to have a meaningful impact on a patient’s health.
Ritter’s leadership team has extensive biotechnology expertise in discovering, developing and commercializing therapeutic products. We have attracted a scientific team comprised of innovative researchers who are world renowned in their knowledge and understanding of the host-microbiome. Combined, our expertise is leading the way in the understanding of the host gut microbiome and the discovery in novel microbiome modulators.
Our lead compound, RP-G28 is currently under development for the treatment of lactose intolerance. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease that affects over 1 billion people worldwide. The product stimulates the growth of lactose-metabolizing bacteria in the colon, which reduces lactose-derived gas production, and thereby mitigates the symptoms of lactose intolerance in the process.
Yahoo Data and NewsCompany Web Site

 

lower_banner

lower_banner-02

  Disclaimer     Financial Glossary

©2013 Investor Awareness, Inc. All rights reserved